HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marras, C Articles by Lang, A E Search for Related Content PubMed PubMed Citation Articles by Marras, C Articles by Lang, A E

Measuring motor complications in clinical trials for early Parkinson’s disease

Division of Neurology, Toronto Western Hospital, University Health Network and University of Toronto, Canada

Correspondence to:
Correspondence to:
Dr A E Lang, Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, 11-MP, 399 Bathurst Street, Toronto, Ontario M5G 2S8, Canada;
lang@uhnres.utoronto.ca

Keywords: Parkinson’s disease; measurement; motor complications

The first 150 words of the full text of this article appear below.

The development of dyskinesias and motor fluctuations is a major concern related to dopaminergic treatment for Parkinson’s disease. These motor complications are common,¹ and can be a significant source of disability.^2,3 Numerous clinical trials have been conducted to compare treatments for their ability to delay, prevent, or reduce the severity of motor complications. Measuring motor complications is challenging because of the number of potentially important aspects, including frequency, intensity, predictability, phenomenology, as well as the need to rely on a subject’s understanding and awareness of these phenomena because they are transient, often under-recognised by the affected patient, and often cannot be observed directly by study personnel.

As shown in table 1, the proportion of subjects experiencing motor complications with initial levodopa therapy recorded by several recent randomised, controlled trials of initial treatment of Parkinson’s disease varies considerably.^4–13 For example, the proportion of subjects recorded as having dyskinesias . . . [Full text of this article]

This article has been cited by other articles:

				R. Katzenschlager, A. Schrag, A. Evans, A. Manson, C. B. Carroll, D. Ottaviani, A. J. Lees, and J. Hobart Quantifying the impact of dyskinesias in PD: The PDYS-26: A patient-based outcome measure Neurology, August 7, 2007; 69(6): 555 - 563. [Abstract] [Full Text] [PDF]

				D Grosset, L Taurah, D J Burn, D MacMahon, A Forbes, K Turner, A Bowron, R Walker, L Findley, O Foster, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis J. Neurol. Neurosurg. Psychiatry, May 1, 2007; 78(5): 465 - 469. [Abstract] [Full Text] [PDF]

				R Mergl, P Mavrogiorgou, U Hegerl, and G Juckel Kinematical analysis of emotionally induced facial expressions: a novel tool to investigate hypomimia in patients suffering from depression J. Neurol. Neurosurg. Psychiatry, January 1, 2005; 76(1): 138 - 140. [Abstract] [Full Text] [PDF]